Capsule Summary Slidesets

Share

Program Content

Activities

  • Daratumumab + IRd in NDMM
    Phase II Trial of Daratumumab + Ixazomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 04, 2018

    Expires: December 03, 2019

  • Novel BiTE AMG 420 in MM
    First-in-Human Phase I Trial of AMG 420, a BiTE Construct Binding to BCMA x CD3, in Heavily Pretreated Patients With Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2018

    Expires: December 05, 2019

  • FORTE: First-Line Carfilzomib-Based Tx
    FORTE: KRd Induction/Consolidation With ASCT vs 12 Cycles of KRd vs KCd Induction/Consolidation With ASCT in ASCT-Eligible Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2018

    Expires: December 05, 2019

  • HOVON 143: IxaDaraDex in NDMM
    Planned Interim Analysis of Phase II HOVON 143 Study of Ixazomib, Daratumumab, and Low-Dose Dex in Unfit, Frail Patients With Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2018

    Expires: December 09, 2019

  • TOURMALINE-MM3
    TOURMALINE-MM3: Phase III Trial of Oral Ixazomib as Maintenance Therapy After ASCT in Patients With Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2018

    Expires: December 09, 2019

  • MAIA: DaraRd in NDMM
    Phase III MAIA: Daratumumab + Len/Dex vs Len/Dex in Transplantation-Ineligible Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2018

    Expires: December 09, 2019

  • LEGEND-2: CAR T in MM
    LEGEND-2 Updated Analysis: Phase I Study of LCAR-B38M CAR T-Cell Therapy in Patients With R/R Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2018

    Expires: December 10, 2019

  • Rd-R vs Cont Rd in NDMM
    Phase III Trial of Rd Followed by R vs Continuous Rd in Intermediate-Fit Elderly Patients With Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2018

    Expires: December 10, 2019

  • STORM: Selinexor in Penta-Ref MM
    Phase II STORM Trial Part 2: Selinexor + Low-Dose Dexamethasone in Penta-Refractory MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2018

    Expires: December 17, 2019

  • GRIFFIN: VRd ± Dara
    GRIFFIN: Efficacy and Updated Safety From Phase II Study of Daratumumab + VRd vs VRd Alone for Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology